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ABSTRACT
Objectives: To systematically review the effectiveness
of community pharmacy-delivered interventions for
alcohol reduction, smoking cessation and weight
management.
Design: Systematic review and meta-analyses. 10
electronic databases were searched from inception to
May 2014.
Eligibility criteria for selecting studies: Study
design: randomised and non-randomised controlled
trials; controlled before/after studies, interrupted times
series. Intervention: any relevant intervention set in a
community pharmacy, delivered by the pharmacy team.
No restrictions on duration, country, age, or language.
Results: 19 studies were included: 2 alcohol
reduction, 12 smoking cessation and 5 weight
management. Study quality rating: 6 ‘strong’, 4
‘moderate’ and 9 ‘weak’. 8 studies were conducted in
the UK, 4 in the USA, 2 in Australia, 1 each in 5 other
countries. Evidence from 2 alcohol-reduction
interventions was limited. Behavioural support and/or
nicotine replacement therapy are effective and cost-
effective for smoking cessation: pooled OR was 2.56
(95% CI 1.45 to 4.53) for active intervention vs usual
care. Pharmacy-based interventions produced similar
weight loss compared with active interventions in other
primary care settings; however, weight loss was not
sustained longer term in a range of primary care and
commercial settings compared with control. Pharmacy-
based weight management interventions have similar
provider costs to those delivered in other primary care
settings, which are greater than those delivered by
commercial organisations. Very few studies explored if
and how sociodemographic or socioeconomic
variables moderated intervention effects. Insufficient
information was available to examine relationships
between effectiveness and behaviour change strategies,
implementation factors, or organisation and delivery of
interventions.
Conclusions: Community pharmacy-delivered
interventions are effective for smoking cessation, and
demonstrate that the pharmacy is a feasible option for
weight management interventions. Given the potential
reach, effectiveness and associated costs of these
interventions, commissioners should consider using
community pharmacies to help deliver public health
services.
Strengths and limitations of this study
▪ To the best of our knowledge, this is the first
systematic review that combines evidence from
community pharmacy-delivered alcohol, smoking
and weight management interventions, and dir-
ectly compares these findings with other primary
care and community healthcare settings.
▪ This review provides healthcare commissioners
with useful evidence on reach, effectiveness and
costs when considering using community phar-
macies to help deliver smoking cessation and
weight management services.
▪ There was insufficient evidence to assess the
effectiveness of community pharmacy-based
interventions on health equity.
▪ The descriptions available did not allow for the
coding of specific aspects of theory and behav-
ioural content of the interventions.
▪ Insufficient information was available to examine
the relationship between intervention effective-
ness and behaviour change strategies and/or
models used, implementation factors, or the
organisation and delivery of interventions.
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INTRODUCTION
A number of agencies and countries, including WHO,
have set a clear strategy for the future of public health.
This agenda is focused on improving the healthy life
expectancy of the population and, where possible, redu-
cing or removing threats to this aim.1 One strand within
this agenda is to create accessible, multidisciplinary net-
works of public health professionals who work within
communities and provide services to address key public
health issues, health inequalities, and ultimately improve
health and well-being. Worldwide, community pharma-
cies may be an important component of this agenda;
WHO acknowledges that community pharmacies and
their staff are easily accessible and, as such, could play a
key role in delivering public health initiatives, especially
in priority areas.2 For example, in England, community
pharmacies are more accessible than general practice
(GP) services.3 A recent study has also demonstrated
that, in England, 89% of the population can walk to a
community pharmacy within 20 min. Significantly, in
areas of highest deprivation, this value increases to
almost 100%—the so-called positive pharmacy care law.4
Community pharmacies could, therefore, be a way of
engaging with hard-to-reach populations.
In view of this, many community pharmacies in some
countries, now offer smoking cessation services, and a
few offer alcohol and weight reduction services.5 These
services are delivered by pharmacists, pharmacy techni-
cians and/or medicine counter assistants, with a view to
modifying health-related behaviours. The specific types
of services are wide ranging and include two main
approaches: pharmaceutical-related (eg, supplying nico-
tine replacement therapy (NRT), monitoring of bio-
chemical markers) and non-pharmaceutical-related (eg,
providing advice on behaviour change strategies), or a
combination of both approaches. Funding arrangements
for these services vary by country; in the UK, at present,
many of these services are commissioned by the local
authority according to local need, and delivered accord-
ing to an agreed framework. Currently, six Local
Pharmaceutical Committees (LPCs) have weight man-
agement services, 14 LPCs have alcohol reduction ser-
vices, and there are 81 stop smoking services.6
In 2008, the Department of Health for England7
stated it was important to develop ‘a sound evidence
base that demonstrates how pharmacy delivers effective,
high quality and value for money services’. Reviews pub-
lished since 2008 have attempted to summarise this evi-
dence base, but the lack of relevant randomised
controlled trials (RCTs) have limited their findings.8–10
However, a scoping search performed in 2013 revealed a
number of relevant RCTs that had, or were about to
report their findings; a number of relevant controlled
trials were also identified, that could usefully inform the
evidence base where there was a lack of evidence from
RCTs. The primary objective of this review, therefore,
was to systematically review the effectiveness of commu-
nity pharmacy-delivered interventions for alcohol
reduction, smoking cessation and weight management.
The secondary objectives were to explore if and how
age, ethnicity, gender and socioeconomic status (SES),
moderate intervention effects; and to describe how the
interventions have been implemented, organised and
delivered.
METHODS
The review was funded by the National Institute for
Health Research Public Health Research Programme
(project number 12/153/52). The review was carried
out using the principles outlined in the Cochrane
Handbook for Systematic Reviews of Interventions.11
The protocol is published in BMC Systematic Reviews,12
and is registered with the International Prospective
Register of Systematic Reviews (PROSPERO
CRD42013005943). A review advisory group comprising
patients, pharmacists and researchers, helped to guide
the research. The review is reported according to the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines.13 14
Interventions
The review included any type of community pharmacy-
delivered intervention aimed at alcohol reduction,
smoking cessation, or weight management; of any dur-
ation, based in any country and of any age. The setting
of interest was the community pharmacy, which was
defined as a pharmacy set in the community, which is
accessible to all and not based in a hospital, clinic or
online. Where a pharmacy is referred to throughout this
paper, we refer to a community pharmacy. There was no
restriction on the type of comparator, which could be a
non-active control, usual care, or another type of active
intervention, set in or out of the community pharmacy.
Participants could be recruited from outside of the com-
munity pharmacy as long as one of the intervention
groups was delivered from the community pharmacy.
The intervention had to be delivered by the community
pharmacist, pharmacy technician or medicines counter
assistant; however, the intervention could also include
other deliverers as part of a multidisciplinary team.
Study design
A broad range of controlled study designs were
included, using the Cochrane Effective Practice and
Organisation of Care (EPOC) study design criteria.15
These included RCTs; non-RCTs (nRCT); controlled
before/after studies (CBA); interrupted time series
(ITS), and repeated measures studies. We included both
fully powered and pilot studies; studies were graded
lower on quality if they were insufficiently powered.
Search strategy
Ten electronic databases were searched: Applied Social
Sciences Index and Abstracts, Cumulative Index to
Nursing and Allied Health Literature, EMBASE,
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International Bibliography of the Social Sciences,
MEDLINE, NHS Economic Evaluation Database,
PsycINFO, Social Science Citation Index, Scopus and
the Sociological Abstracts; from inception to May 2014
(see online supplementary file 1). Supplementary
searches to identify published, unpublished and
ongoing studies included bibliographies, contacting
experts, grey literature (OpenGrey, Social Care Online,
Prevention Information & Evidence elibrary and Nexus
UK), study registers (International Standard Registered
Clinical/soCial sTudy Number registry and the National
Research Register) and website (Google).
Outcomes
Interventions for alcohol reduction and smoking cessa-
tion had to report a relevant behavioural outcome, and
interventions for weight had to report an anthropomet-
ric outcome. These outcomes were considered the
primary outcomes, and could be measured or self-
reported. Where studies reported if and how sociodemo-
graphic (age, ethnicity, gender) and/or SES (education,
income, occupation, social class, deprivation or poverty)
moderated intervention effects on the primary out-
comes, this is reported in the review.
The review also describes how the interventions have
been organised, implemented and delivered using the
methodological tool for the assessment of the imple-
mentation of complex public health interventions in sys-
tematic reviews, developed by Egan et al16 for the
workplace, and adapted by Bambra et al17 for obesity
interventions. The Behaviour Change Wheel18 and the
Nuffield Intervention Ladder19 were used to broadly
describe the behavioural strategies, intervention func-
tions and policy categories of the interventions.
Data extraction and quality appraisal
Three reviewers (CO, HM, SS) screened the titles and
abstracts and two reviewers (CO, TB) screened the full-
text articles. Data extraction and quality assessment were
conducted independently by TB and one other reviewer
(from among AT, CO, CS, HM, LN, LS, SS). Study
quality was appraised using the Effective Public Health
Practice Project Quality Assessment Tool for Quantitative
Studies,20 which is recommended by the Cochrane
Public Health Review Group.21 Studies were assessed for
quality using six criteria: selection bias, study design,
confounders, blinding, data collection methods and
withdrawals/dropouts. Each study was given an overall
(global) rating based on the ratings for the six criteria:
‘strong’ (no ‘weak’ ratings), ‘moderate’ (one ‘weak’
rating) and ‘weak’ (two or more ‘weak’ ratings). Any dis-
crepancies in the data extraction or quality assessment
were resolved through discussion, or referred to a third
reviewer (CS) for final assessment. Extraction of context-
ual data was conducted by one reviewer (CS) and
checked by another (TB). Assessment of behaviour
change strategies used was conducted by one reviewer
(CS) and checked by two others (FS and LS).
Analysis and synthesis
Narrative synthesis was conducted for all the included
interventions. Owing to the heterogeneity of the studies,
it was only possible to conduct meta-analyses for the
smoking cessation studies. The smoking data was analysed
(AK) using binomial-normal random effect model
(R package meta). In order to explain the observed
heterogeneity between studies, four different meta-regres-
sion models were fitted, accounting for whether the com-
parator was an active control or usual care, duration of
the intervention and the global quality assessment
ratings. Q-statistics and the percentage of heterogeneity
between studies were reported for each meta-regression
model. The most optimal meta-regression model was
chosen using a minimum Akaike Information criterion.
Owing to the limited available data and lack of inform-
ative priors, subgroup analysis by demographic or SES
was not considered. A funnel plot for the smoking cessa-
tion RCTs was carried out to indicate the possible pres-
ence of publication bias and other biases.
RESULTS
The electronic search identified over 19 000 records, of
which 72 full-text articles were screened for eligibility; 19
studies (from 23 articles) were included, and 49 were
excluded. Five excluded studies22–26 (from six articles)
were pharmacotherapy plus lifestyle advice interventions
in participants with comorbidities. These studies were
excluded because the primary focus was not alcohol,
smoking or weight management; these interventions
focused on self-management of a chronic condition.
The process of inclusion and exclusion of studies are
shown in figure 1.
Study characteristics
Tables 1–3 provide the main study characteristics for all
19 interventions (see online supplementary file 2) for
detailed study characteristics, including sociodemo-
graphic and SES). There were 2 alcohol reduction inter-
ventions,27 28 12 smoking cessation interventions29–40
and 5 weight management interventions.41–45 There
were 15 RCTs, 2 nRCTs25 33 44 and 2 CBAs.29 29 42 There
were 17 published journal articles and two reports.28 42
Eight studies were conducted in the UK,27–29 33 36 38 42 43
four in the USA,30 35 41 44 two in Australia31 39 and one
each in Canada,32 Denmark,40 Japan,37 The
Netherlands34 and Thailand.45 All studies were of adults.
Fourteen studies reported on funding; types of funding
sources included academic research bodies,
health-related institutions, commercial organisations and
pharmaceutical companies.
Three studies29 42 43 recruited participants from areas
of high deprivation, and compared a pharmacy-based
setting with other settings. Twelve studies recruited parti-
cipants within the community pharmacy; other recruit-
ment settings included hospital/primary care units, via
telephone and a community health centre. Types of
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pharmacies included single outlets, small chains and
large chains; set in rural, urban and a combination of
both geographical settings. The number of pharmacies
included within each study ranged from one to over
200. Participant sample size ranged from 28 to around
7000, comprising approximately 13 500 service users in
total. Mean age ranged from 24 to 60 years; there was a
majority of females across all studies, particularly in the
weight management studies. Duration of follow-up
ranged from 5 to 56 weeks.
In terms of data analysis, only four studies assessed
whether sociodemographic variables moderated the
effect of interventions; four studies28 38 42 43 assessed
any differential effects of gender, and one of these also
assessed age.42 No study assessed any differential effects
of SES. Few studies used regression analysis to assess the
influence of sociodemographic or socioeconomic vari-
ables on change from baseline, as potential predictors of
outcomes within intervention groups, or to explain
retention.
Quality assessment
The studies were assessed for quality using six criteria
and assigned a global rating; six studies were rated
‘strong’, four studies ‘moderate’ and nine studies ‘weak’
(see online supplementary file 3). Participants were not
obtained from a randomly selected sample in any of the
studies. Five studies reported a low attrition rate, with
follow-up of at least 80% of participants. Only five
studies were sufficiently powered. Six studies conducted
intention-to-treat analyses. Fifteen studies imputed data
from baseline or last follow-up, or made assumptions
about dropouts (eg, assumed that dropouts had not
stopped smoking/not lost weight). Six studies used hier-
archical modelling techniques to adjust for potential
pharmacy or pharmacist-level effects on individual par-
ticipant outcomes. None of the studies reported details
about whether the intervention was delivered as
intended, for example, by observation of sessions,
quality control audits, or staff and researcher records.
Implementation of the interventions
Very few studies reported any degree of consultation or
collaboration, with stakeholders as part of the planning
process, or during delivery of the intervention (see
online supplementary file 4). Both the brief alcohol
reduction interventions consulted with pharmacists
during the planning stages.28 27 The smoking cessation
study by Hoving et al34 collaborated with a national
charity on smoking and health, and together they devel-
oped the intervention. The smoking cessation study by
Costello et al32 was nested within a ‘host’ study called
‘STOP’, which collaborated with different community
and regional partners in many different ways during the
planning and delivery of the intervention. In the major-
ity of interventions, regardless of their target behavioural
or health outcome, pharmacists received reimbursement
for providing the intervention; this appears important in
order for the intervention to be sustainable.32 36
Organisation and delivery of the interventions
Sixteen interventions were delivered by the community
pharmacy staff; one photoageing intervention31 was
delivered by a research pharmacist employed by the
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.
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Table 1 Summary characteristics and outcomes of alcohol reduction interventions (further details are presented in online supplementary files 2–8)
AUDIT total scores FAST total scores
Study ID
Study
characteristics Description
Baseline
behaviour
Mean
change
from
baseline* 95% CI N
Mean
change
from
baseline* SD N
Global
quality
rating† Effectiveness‡
Cost-
effectiveness
Differential
effects§
Dhital
et al27
Design: RCT
Duration: 12
weeks¶
Country: UK
Number of
pharmacies: 16
Number of
participants: 407
Mean age:
I:39.6; C: 40.5
% female: I:
47.8; C: 43.6
Brief alcohol
advice
AUDIT
Scores:
11.93 (SD
3.24)
−0.11 −0.82 to 0.61 168 Strong ↔ NR NR
Usual care
control
AUDIT
Scores:
11.53 (SD
3.19)
−0.74
p=0.24
−1.47 to 0.00 158
Watson
and
Stewart28
Design: RCT
Duration: 26
weeks
Country: UK
Number of
Pharmacies : 20
Number of
participants: 69
Mean age: NR
% female: I:
48.1; C: 57.1
Brief alcohol
advice
FAST score
≥3: 29.2%
2.25
0.50
3.20
0.71
4M
2F
Weak ↔ Cost analysis
only
NR
Usual care
control
FAST score
≥3: 24.6%
−1.25
0.75
NS
2.87
1.67
4M
8F
*p Values were extracted directly from the study papers and relate to between group differences.
†Global rating: ‘strong’=no ‘weak’ ratings, ‘moderate’=one ‘weak’ rating and ‘weak’=two or more ‘weak’ ratings.
‡Effectiveness was assessed using between group differences.
§Differential effects: age, gender, ethnicity or socioeconomic status (education, income, occupation, social class, deprivation or poverty).
¶From baseline to last follow-up.
↑, intervention effective; ↓, intervention not effective; ↔, no statistically significant between group difference; AUDIT, Alcohol Use Disorders Identification Test; C, control group; F, female; FAST,
Fast Alcohol Screening Tool; I, intervention group; M, male; NR, not reported; NS, non-significant; RCT, randomised controlled trial.
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Table 2 Summary characteristics and outcomes of smoking cessation interventions (further details are presented in online supplementary files 2–8)
Study ID Study characteristics Description
Baseline
behaviour Quit rate*
Global
quality
rating† Effectiveness‡
Cost-
effectiveness***
Differential
effects§
Bauld et al29 Design: CBA
Duration: 52 weeks¶
Country: UK
Number of pharmacies:
>200
Number of participants:
1785
Mean age: I: 44.0; C: 49.8
% female: I: 56.5; C: 65.5
Individual pharmacy-
based NHS smoking
cessation service + NRT
21+ cigarettes/
day: 396 (40.1%)
38/1374
(2.8%)
Weak ? Yes both
services
compared to
control
NR
Group community-based
NHS smoking cessation
service + NRT
21+ cigarettes/
day: 169 (41.6%)
26/411 (6.3%)
p=0.001
Bock et al30 Design: RCT
Duration: 26 weeks
Country: USA
Number of pharmacies: 2
Number of participants:
299
Mean age: I1: 45.5; I2:
46.5; C: 42.3
% female: 59.0
Smoking cessation
training for pharmacists +
tailored counselling using
computer software + NRT
Number of
cigarettes
smoked/day:
18.2;
Fagerström score:
5.3
28/100
(28.0%)
Moderate ↑ NR NR
Smoking cessation
training for pharmacists +
tailored counselling using
computer software
Number of
cigarettes
smoked/day:
17.7;
Fagerström score:
5.1
15/100
(15.0%)
Observation only control
(not randomised)
Number of
cigarettes
smoked/day:
13.8;
Fagerström score:
4.9
8/99 (8.1%)
p<0.01
Burford et al31 Design: RCT
Duration:26 weeks
Country:Australia
Number of pharmacies:8
Number of
participants:160
Mean age:I:24.2; C:25.1
% female: I:68.7; C:56.2
Smoking cessation
advice + computer-
generated photoageing
Fagerström score:
2.87;
>21 cigarettes/
day smoked: 10%
11/80 (13.8%) Moderate ↑ Yes NR
Smoking cessation
advice
Fagerström score:
2.96;
>21 cigarettes/
day smoked: 15%
1/80 (1.3%)
p=0.003
Costello et al32 Design: RCT
Duration:5 weeks
Country:Canada
Number of pharmacies:98
1 week then fortnightly
visit for NRT plus 3
sessions brief
behavioural counselling
HSI ≥3: 91.8% 612/3503
(17.5%)
Weak ↔ NR NR
Continued
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Table 2 Continued
Study ID Study characteristics Description
Baseline
behaviour Quit rate*
Global
quality
rating† Effectiveness‡
Cost-
effectiveness***
Differential
effects§
Number of
participants:6987
Mean age:NR
% female: I:54.4; C:54.9
5 weeks NRT at initial
visit plus 1 session brief
behavioural counselling
HSI ≥ 3: 91.4% 604/3350
(18.0%)
p=0.4
Crealey et al
1990<CE:
Please check
year is not
matching with
reference list.>
Design:nRCT
Duration:26 weeks
Country:UK
Number of pharmacies:2
Number of
participants:169
Mean age:NR
% female: NR
Behavioural support, 67%
(35/52) nicotine gum
NR 24/52 (46.2%) Weak ↑ Yes NR
Nicotine gum only NR 3/48 (6.3%)
Control (expressed wish
to stop smoking)
NR 0/60 (0%)
p<0.01 (I vs C)
Hoving et al34 Design: RCT
Duration:52 weeks
Country:Netherlands
Number of pharmacies:65
Number of
participants:545
Mean age:I:46; C:47
% female: I:53; C:54
Computer-generated
tailored advice
Number of
cigarettes
smoked/day: 22
2/256 (0.8%) Strong ↔ NR NR
‘Thank you’ letter control Number of
cigarettes
smoked/day: 21
2/289 (0.7%)
NS
Howard-Pitney
et al35
Design: RCT
Duration:26 weeks
Country:USA
Number of pharmacies:5
Number of
participants:410
Mean age:I:36.3; C:34.7
% female: I:1; C:1
Advice and support +
nicotine patch
Number of cans
chewed/week: 3.9
78/206
(37.9%)
Moderate ↔ NR NR
Advice and support +
placebo patch
Number of cans
chewed/week: 4.1
69/204
(33.8%)
p<0.40
Maguire et al36 Design: RCT
Duration:52 weeks
Country:UK
Number of pharmacies:51
Number of
participants:484
Mean age:I:42; C:38
% female: I:40; C:44
Behavioural support, 87%
(230/265) NRT
Number of
participants 10–
20 cigarettes/day:
197/265
38/265
(14.3%)
Weak ↑ NR NR
Ad hoc advice, 84%
(183/219) NRT
Number of
participants 10–
20 cigarettes/day:
121/219
6/219 (2.7%)
p < 0.001
Continued
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Table 2 Continued
Study ID Study characteristics Description
Baseline
behaviour Quit rate*
Global
quality
rating† Effectiveness‡
Cost-
effectiveness***
Differential
effects§
Mochizuki
et al37
Design: RCT
Duration:12 weeks
Country:Japan
Number of pharmacies:14
Number of participants:28
Mean age:I:44.1; C:49.1
% female: I:18.2; C:18.8
Nicotine gum plus advice
on usage, initial and
follow-up cessation
advice
Number of
cigarettes
smoked/day:
23.0;
Fagerström score:
4.56
5/11 (45.5%) Strong ↔ NR NR
Nicotine gum plus advise
on usage
Number of
cigarettes
smoked/day:
25.7;
Fagerström score:
6.31
5/16 (31.3%)
OR=1.83, NS
Sinclair et al38 Design: RCT
Duration:36 weeks
Country:UK
Number of pharmacies:62
Number of
participants:492
Mean age:I:41.7; C:41.5
% female: I:61.2; C:62.7
Training pharmacists/
assistants in smoking
cessation behaviour
change + NRT
Fagerström score:
5.2
26/217
(12.0%)
Strong ↔ Yes NR
Standard professional
pharmacy support + NRT
Fagerström score:
5.2
19/257 (7.4%)
p=0.089
Sonderskov
et al40
Design: RCT
Duration:26 weeks
Country:Denmark
Number of pharmacies:42
Number of
participants:522
Mean age:I(21 mg):39.1;
C(21 mg):39.9; I
(14 mg):38.2; C
(14 mg):38.9
% female: I(21 mg):47.5;
C(21 mg):52.5; I
(14 mg):51.7; C
(14 mg):48.3
21 mg nicotine patches Fagerström score:
7.0
15/132
(11.4%)
Strong ↑ 21 mg;
↔ 14 mg
NR No
(gender)
Placebo Fagerström score:
8.1
6/142 (4.2%)
p<0.05
14 mg nicotine patches Fagerström score:
6.1
27/119
(22.7%)
Placebo Fagerström score:
6.1
23/125
(18.4%)
NS
Continued
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local university in collaboration with the community
pharmacist, who delivered standard smoking cessation
advice (see online supplementary file 5). Another
smoking cessation intervention was conducted by a
research pharmacist as part of an MSc project; the
research pharmacist delivered the hospital-based inter-
vention programme, and the community pharmacists
delivered the community-based intervention pro-
gramme.39 One smoking cessation intervention involved
the postal delivery of a computer-generated letter.34
Most studies included standardised staff training,
although this was usually brief (ranging from 2 h to
2 days). Two smoking cessation studies mentioned they
also included role play as part of the training,30 35 and
two weight management studies reported ‘practical
tasks’ as part of the training.43 45
In terms of quality assurance, one alcohol reduction
intervention provided a 2 h evening follow-up training
session during the intervention to address challenges
and share learning across the pharmacists who were deli-
vering the intervention.27 In two smoking cessation
studies,33 36 a researcher visited the pharmacists after
the group training session, to provide support and to
address any queries they had in implementing the train-
ing. In one smoking cessation study that was organised
by a pharmaceutical company,40 the company contacted
pharmacies at least once a week during the intervention.
Behaviour change strategies used in the interventions
Seven studies reported that a behavioural theory/model
informed the intervention and provided details of
behaviour change strategies used; six studies only
reported details of behaviour change strategies used; six
studies reported no relevant information (see online
supplementary file 6). The most commonly reported
theoretical model was the Transtheoretical (‘Stages of
Change’) Model, which was reported by six studies;
motivational interviewing was reported by five studies.
The descriptions available did not allow for the coding
of specific aspects of theory and behavioural content.
Using the Behaviour Change Wheel,18 the intervention
functions of the majority of interventions were ‘educa-
tion’ and ‘enablement’. In addition, interventions that
included the provision of NRT or commercial weight
management programmes or products free of charge,
were also deemed to include ‘incentivisation’. Using the
policy category of the Behaviour Change Wheel,18 all
the interventions were categorised as ‘service provision’.
Six of these interventions also included ‘communica-
tion/marketing’. No other policy categories were identi-
fied. Using the Nuffield intervention ladder,19 most
interventions were coded as ‘enable choice’.
EFFECTS OF INTERVENTIONS
Alcohol reduction interventions (n=2)
There were two RCTs of brief alcohol reduction inter-
ventions (table 1) compared with usual care or
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Table 3 Summary characteristics and outcomes of weight management interventions (further details are presented in online supplementary files 2–8
BMI (kg/m2) WC (cm) WT (kg)
Study ID
Study
characteristics N Description
Mean
change
from
baseline§ SD/95% CI
Mean
change
from
baseline§ SD
Mean
change
from
baseline§ SD/95% CI
Global
quality
rating* Effectiveness†
Cost-
effectiveness
Differential
effects‡
Ahrens et al41
2011
Design: RCT
Duration: 22 weeks¶
Country: USA
Number of
pharmacies: 1
Number of
participants: 95
Mean age: I: 47.6;
C: 47.8
% female: 87
Baseline BMI: I:
29.5; C: 29.0
45 Meal
replacement diet
NR NR −8.08 NR −5.6 NR Weak ↔ NR NR
43 Low calorie diet NR NR −7.82 NR −5.2 NR
Bush et al42 Design: CBA
Duration: 15 weeks¶
Country: UK
Number of
pharmacies: 12
Number of
participants: 451
Mean age: I: 38.9;
C: 42.6
% female: I: 87; C:
85
Baseline BMI: I:
33.0; C: 35.6
60 Pharmacy-based
diet + physical
activity
−1.3 0.4 −6.5 1.6 −3.4 1.1 Weak ? Unclear which
service was
more cost
effective
Yes,
demographics
of participants
differed
significantly
between
settings
22 GP-based diet +
physical activity
−0.8 0.7 −4.9 2.6 −2.3 1.9
Jolly et al43** Design: RCT
Duration: 52 weeks¶
Country: UK
Number of
pharmacies:NR
Number of
participants: 740
Mean age: Ph: 48.9;
Ex: 49.7; WW: 50.7;
SW: 48.8;RC: 48.8;
NHS SD: 48.8; GP:
50.5; POC: 47.5
% female: Ph: 73;
Ex: 75; WW: 72;
70 Pharmacy-based
diet + physical
activity
−0.31 −0.7 to 0.0 NR NR −0.66 −1.7 to 0.4 Moderate ↔ Cost analysis
only,
commercial
organisations
lower cost
than GP and
pharmacy-
based
services
No (gender)
100 Exercise only
control
−0.45 −0.8 to −0.1 NR NR −1.08 −2.1 to −0.1 ‡
100 Weight Watchers −1.17 −1.7 to −0.7 NR NR −3.46 −4.8 to −2.1 ↑
100 Slimming World −0.71 −1.0 to −0.4 NR NR −1.89 −2.9 to −0.9 ↔
100 Rosemary
Conley
−0.75 −1.1 to −0.3 NR NR −2.12 −3.4 to −0.9 ↔
100 NHS Size Down −0.67 −1.0 to −0.3 NR NR −2.45 −3.6 to −1.3 ↔
70 GP −0.32 −0.7 to 0.1 NR NR −0.83 −2.0 to 0.4 ↔
100 Participants own
choice
−0.90 −1.3 to −0.5 NR NR −2.15 −3.4 to −0.9 ↔
Continued
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Table 3 Continued
BMI (kg/m2) WC (cm) WT (kg)
Study ID
Study
characteristics N Description
Mean
change
from
baseline§ SD/95% CI
Mean
change
from
baseline§ SD
Mean
change
from
baseline§ SD/95% CI
Global
quality
rating* Effectiveness†
Cost-
effectiveness
Differential
effects‡
SW: 65; RC: 69;
NHS SD: 64; GP:
67; POC: 70
Baseline BMI: P:
33.4; Ex: 33.9; WW:
34.0; SW: 33.8; RC:
33.4; NHS SD: 33.8;
GP: 33.1; POC: 33.4
Malone and
Alger-Mayer44
Design: nRCT
Duration: 26 weeks¶
Country: USA
Number of
pharmacies: NR
Number of
participants: 30
Mean age: I: 44.9;
C: 42.8
% female: I: 93; C:
80
Baseline BMI: I:
48.3; C: 42.8
15 Pharmacist
support + orlistat
+ usual
outpatient care
NR NR NR NR −3.5 2.9 Weak ↔ NR NR
15 orlistat + usual
outpatient care
NR NR NR NR −3.0 5.2
Phimarn
et al45
Design: RCT
Duration: 16 weeks¶
Country: Thailand
Number of pharmac
ies: 1
Number of
participants: 66
Mean age: I: 60.1;
C: 59.1
% female: I: 75.8; C:
84.8
Baseline BMI: I:
27.5; C: 27.7
33 Pharmacist
individual support
−0.8 0.07 0.1 0.03 −0.82 0.29 Strong ↔ NR NR
33 Primary care unit
group support
0.19 0.04 −0.28 0.08 0.92 0.19
*Global rating: ‘strong’=no ‘weak’ ratings, ‘moderate’=one ‘weak’ rating and ‘weak’=two or more ‘weak’ ratings.
†Effectiveness was assessed using between group differences.
‡Differential effects: age, gender, ethnicity or socioeconomic status (education, income, occupation, social class, deprivation or poverty).
**All intervention groups in the Jolly trial were compared to the exercise only control group (intervention groups were not directly compared).
§p Values were extracted directly from the study papers and relate to between group differences.
¶From baseline to last follow-up.
↓, intervention not effective; ↑, intervention effective; ↔, no statistically significant between group difference; ?, unable to assess effectiveness/cost-effectiveness; BMI, body mass index; C, control group; CBA, controlled
before-after study; Ex, exercise only control; GP, general practitioner; NHS SD, NHS Size Down; NHS, National Health Service; NR, not reported; nRCT, non-randomised controlled trial; NS, non-significant; Ph,
Pharmacy-based diet + physical activity; POC, participants own choice; RC, Rosemary Conley; RCT, randomised controlled trial; SW, Slimming World; WC, waist circumference; WT, weight; WW, Weight Watchers.
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leaflet-only control (see online supplementary files 7
and 8). One RCT27 used the Alcohol Use Disorders
Identification Test total scores (AUDIT), and reported a
baseline AUDIT score of 11.93. The other RCT28 used
the Fast Alcohol Screening Tool (FAST), and reported
29.2% of participants scoring ≥ 3 at baseline. Possible
‘harmful or hazardous’ alcohol consumption, but not
alcohol dependence is indicated with an AUDIT score
8–19 or a FAST score of 3–16. Global quality ratings
were ‘strong’ for one study27 and ‘weak’ for the other,28
which was a small pilot study. Both studies involved
one-to-one contact with the pharmacist. Dhital et al27
encouraged self-directed behaviour change; the inter-
vention included reflection and feedback of the AUDIT
score.
Behavioural outcomes
Neither intervention significantly reduced alcohol scores
compared with control. At 12 weeks, the AUDIT total
change score did not differ significantly between the two
groups and did not change significantly between base-
line and follow-up in either group. Twelve-week AUDIT
between group difference, adjusted for pharmacist
gender, age, ethnicity and education, was −0.57 (95% CI
−1.59 to 0.45). There was no significant difference
between FAST score for the intervention group com-
pared with control at 3 or 6 months, adjusted for base-
line FAST: the difference between groups was −1.84
(95% CI −4.49 to 0.82). At 6 months, there was substan-
tially lower follow-up of intervention participants
(22.2%) compared with control participants (33.3%).
Costs
Cost-effectiveness of community pharmacy-based brief
alcohol reduction interventions cannot be ascertained;
only one pilot study28 reported direct intervention costs.
Differential effects by demographic or socioeconomic factors
One pilot study28 reported change in FAST scores by
gender within the intervention and control groups.
However, the study was not powered to detect differ-
ences between the two groups.
Smoking cessation interventions (n=12)
There were 10 RCTs,30–32 34–40 1 nRCT33 and 1 CBA29 of
smoking cessation interventions (table 2). Global quality
ratings were ‘strong’ for four studies, ‘moderate’ for
three studies, and ‘weak’ for five studies. Eleven studies
carried out analyses with the assumption that those lost
to follow-up had not stopped smoking. Half (6/12) the
smoking cessation interventions relied on self-reported
change in smoking behaviours,32 34 37 38–40 and half
used biochemical measures (carbon monoxide (CO) or
cotinine levels).29–31 33 35 36
Ten studies included NRT (in either the intervention
or control group or both).29 30 32 33 35–40 Seven studies
evaluated some form of behavioural support.30 32–34 36–38
Two studies evaluated the effect of intervention setting;
one study assessed behavioural support plus NRT pro-
vided in a hospital outpatient setting compared with
pharmacy setting.39 Another compared individual
pharmacy-based behavioural support plus NRT with
group-support provided in a community setting.29 One
study31 evaluated the effect of a photoageing
intervention.
Despite a variety of different components being evalu-
ated within the individual interventions, the studies were
grouped together to assess the effectiveness of any type
of community pharmacy-delivered intervention for
smoking cessation compared with either an active
control or a non-active/usual care comparator. ‘Usual
care’ varied between studies but was, in general, a
minimal intervention, such as observation only, ad hoc
smoking cessation advice or a thank you letter. However,
in one study, the control group received placebo nico-
tine patches40 and in two studies the control group
received standard cessation advice plus NRT.36 38
Behavioural outcomes
Five of the 12 studies demonstrated effectiveness com-
pared with control. In addition, Bauld et al29 evaluated
one-to-one pharmacist support with group-based
smoking cessation clinics based in the community; the
group-based service attracted fewer clients but was more
effective.
The five effective studies included:
▸ An American RCT30 of additional training to pharma-
cists to enable them to provide a tailored counselling
service with and without NRT, compared with a non-
randomised control group that received observation
only, showed a significant increase in validated 7-day
point prevalence at 6 months (28% for counselling
and NRT, 15% for counselling, 8% for control).
▸ An Australian RCT31 of a computer-generated photo-
ageing service (demonstrating the detrimental effects
on facial physical appearance of smoking) in addition
to standard smoking cessation advice from a pharma-
cist, was effective in stopping young people (mean
age 24 years) smoking compared to control using
CO-validated measures (13.8% n=22/80 vs 1.3%
n=11/80) at 6 months.
▸ A cost-effectiveness study33 in two UK pharmacies
compared a behavioural intervention group based on
the Pharmacist Action on Smoking (PAS) model with
a control group that received nicotine gum, and
another control group who expressed a wish to stop
smoking. At 6 months, there was a statistically signifi-
cant difference in cessation rates between interven-
tion and control groups. Six-month CO-verified
abstinence was 46% in the intervention group, 6% in
the nicotine gum control group, and 0% in the
control group that expressed a wish to stop smoking.
▸ A UK RCT36 compared an intervention based on the
PAS model to ad hoc smoking cessation advice; over
80% in each group also had NRT. The PAS interven-
tion significantly increased validated smoking
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cessation compared with control at 12 months (14.3%
vs 2.7%).
▸ A Danish study40 evaluated the effect of two different
strengths of nicotine patches compared to placebo.
Those smoking ≥20/day at baseline were randomised
to 21 mg patches or placebo, those smoking <20/day
at baseline were randomised to 14 mg patches or
placebo. Self-reported point prevalence included par-
ticipants who had one episode of smoking (<6 days).
At 26 weeks, the intervention was effective for those
smoking ≥20/day at baseline (11% vs 4.2%) but not
effective for lighter smokers (22.7% vs 18.4%) com-
pared with the respective placebo groups.
Meta-regression and meta-analysis
Meta-regression of ORs of smoking cessation between
the intervention and the control groups was under-
taken; in model 1, a random effects model was fitted
including all the RCTs. The pooled OR for the interven-
tion effects was 1.85 (95% CI 1.25 to 2.75), an indica-
tion of the positive effect of the interventions on
smoking cessation. However, there was 72% unexplained
differences between the studies. In model 2, a
meta-regression model was fitted accounting for
whether a study had an active comparator or non-
active/usual care comparator. The pooled ORs were
1.21 (95% CI 0.86 to 1.71) and 2.56 (95% CI 1.45 to
4.53) for the active comparator or non-active/usual care
comparator, respectively (figure 2).
As expected, there was a larger effect when compared
with non-active/usual care comparator than with active
comparator. The proportion of unexplained heterogen-
eity reduced to 52%. In model 3, a meta-regression
model was fitted accounting for whether a study had an
active comparator or a non-active/usual care compara-
tor, and also the intervention duration; the unexplained
heterogeneity reduced to 27.2% with a non-significant
Q-statistic test (10.99, p <0.2026). In model 4, quality
rating was accounted for; quality rating did not appear
to contribute much to the model after accounting for
intervention duration, and whether a study had an active
comparator or a non-active/usual care comparator.
Figure 3 shows a meta-analysis of smoking cessation
accounting for global quality rating, and shows that most
variations between studies are from studies rated as
‘moderate’ or ‘weak’ quality. A funnel plot demonstrated
asymmetry, with larger studies showing effects closer to
the null than smaller studies. Such a pattern is compat-
ible with publication bias, on the assumption that
smaller studies with uninteresting effects are withheld
from publication. However, the funnel plot must be
interpreted with caution, taking into account that it con-
tains only 10 studies, which is the recommended study
size threshold for creating such plots.11
Costs
Four studies reported cost-effectiveness analyses; the
costs and benefits differed between the studies, and
costs years ranged from 1995 to 2011, making compari-
sons across the analyses difficult. All four studies used
quit rates observed within the trials, these ranged from
2.8% to 12% for UK pharmacist-based behavioural
support with NRT.
By comparison with a self-quit attempt, the incremen-
tal cost per Quality Adjusted Life Year was £2600 for
pharmacy one-to-one counselling, and £4800 for group
community-based NHS smoking cessation service.29
Incremental Cost Effectiveness Ratios (ICER) per
Figure 2 Meta-analysis of smoking cessation accounting for whether active comparator or non-active comparator.
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additional quitter ranged from £79 to £509 for
pharmacist-based behavioural support with NRT. The
ICER per additional quitter using photoageing was $A46
(Australian dollars 2011).31 In summary, three UK
pharmacy-delivered interventions appeared cost effective
across a range of quit rates, and an Australian photoage-
ing intervention was cost effective compared to standard
advice among young adults.
Differential effects by demographic or socioeconomic factors
A Danish study40 evaluated the effect of two different
strengths of nicotine patches compared with placebo.
There were no differences in smoking cessation rates
between men and women according to starting dose
and treatment.
Weight management interventions (n=5)
There were three RCTs,41 43 45 one nRCT44 and one
CBA42 of weight management interventions (table 3).
Global ratings were ‘strong’ for one study, ‘moderate’ for
one study, and ‘weak’ for three studies. Three
studies42 43 45 compared a pharmacy-based intervention
with similar interventions in other primary care settings,
and commercial programmes in community settings.
One study41 compared a meal replacement diet with a
conventional low-energy diet (identical recommended
total daily energy intake); both interventions were set in
a pharmacy. One small study44 assessed the added value
of community pharmacy support for an obesity
management intervention that included orlistat and an
outpatient nutrition programme.
Anthropometric outcomes
Three studies reported body mass index (BMI), three
studies reported waist circumference (WC) and all five
studies reported weight (WT). None of the studies found
a significant difference in favour of a pharmacy-delivered
intervention compared with the comparator, for any
anthropometric outcome. However, all comparators are
‘active’ interventions (smoking cessation studies demon-
strated larger effect when compared with non-active con-
trols compared to active controls). One UK RCT43
compared seven groups (Weight Watchers, Slimming
World, Rosemary Conley, Size Down an NHS community-
based group, GP, Pharmacy, participants’ own choice to
an exercise-only control group). This study compared
each intervention group with a control group, and was
not designed to directly compare the active interventions
which were delivered across different settings. All, except
the GP and pharmacy groups, resulted in significant
weight loss at 1 year compared with baseline. Mean
weight loss at 1 year, with baseline value used for imput-
ation, was 0.8 kg (SD 4.7 kg) for primary care (GP and
pharmacy) and 2.5 kg (SD 6.2 kg) for commercial pro-
grammes. Only the Weight Watchers group demonstrated
significant weight loss at 1 year compared to control.
One CBA42 study compared diet and physical activity
in a pharmacy to a GP-based intervention: both groups
Figure 3 Meta-analysis of smoking cessation accounting for global quality rating.
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appeared to reduce BMI, WC and WT at follow-up (stat-
istical significance not reported). Despite participants
choosing the service, there was very high attrition
(93%). One study41 demonstrated significant and similar
amounts of weight loss from baseline to follow-up for
participants in a meal replacement group, or a low-
calorie diet group (both pharmacy-delivered). In
another study, pharmacy-based support in addition to
orlistat did not improve weight loss.44 Another study
demonstrated no significant improvement in weight
from baseline to follow-up for participants receiving
group-based support in a primary care unit compared
with individual support from a pharmacist.45
Costs
Two trials reported intervention costs, one of which also
reported costs per kg weight lost.42 The Jolly et al43 trial
reported similar costs (£112) for both the pharmacy
group and the GP group; both settings had higher costs
compared with commercial weight management pro-
grammes (£71–£77), the NHS community-based group
costs fell in-between at £92.
A study42 of weight management programmes based
in pharmacy or GP settings reported costs ((£126.90 per
participant (n=183) in the pharmacy intervention and
£100.60 per participant (n=268) in the GP interven-
tion)), that were broadly similar to that of the pharmacy-
based group in the Jolly trial. It is unclear which pro-
vider type delivered the intervention more cost-
effectively; at session 12, the ICER (£ per kg per partici-
pant) cost −£8.29 through pharmacy providers (favours
GP). Conversely, at the final session 15, the ICER was
£2.91 through GP providers (favours Pharmacy).
Differential effects by demographic or socioeconomic factors
In a study of weight management programmes in
various commercial, primary care and NHS settings,
there was no statistically significant interaction between
gender and the type of weight management pro-
gramme.43 Bush et al42 compared a weight management
programme set in pharmacies with the same programme
set in GP surgeries. Female participants in GP surgeries
lost a significantly larger proportion of their initial
weight than female participants in pharmacies; partici-
pants aged 40–49 years lost a greater proportion of their
initial weight at GP providers than at pharmacy
providers.
DISCUSSION
Community pharmacy-delivered smoking cessation inter-
ventions including behavioural support and/or NRT, are
effective and cost effective, particularly when compared
with usual care. The pooled ORs for smoking cessation
were 1.21 (95% CI 0.86 to 1.71) and 2.56 (95% CI 1.45
to 4.53) for active control and usual care, respectively.
The heterogeneity of types of interventions precluded
the ability to evaluate effectiveness by specific types of
interventions. There was little evidence comparing
pharmacy-delivered smoking cessation with smoking ces-
sation delivered in other settings. This was in contrast
with the majority of the weight management evidence
which compared active interventions in various settings.
Although there was no significant difference in weight
loss between active interventions in different settings;
pharmacy-based interventions produced similar amounts
of weight loss (3–5 kg) from baseline to short-term
follow-up (6 months or less), compared with active
interventions in other primary care settings. There was
insufficient evidence to evaluate community pharmacy-
delivered interventions for alcohol reduction.
Community pharmacy-delivered smoking cessation
interventions are cost-effective (compared to self-quit or
standard care) across a range of quit rates. Cost-effective-
ness of pharmacy-delivered weight management inter-
ventions is unclear; they have similar provider costs to
those delivered in other primary care settings, which are
greater than those delivered by commercial organisa-
tions. This review aimed to extract information on inter-
vention costs and potential cost savings; however, it is
not a review of economic evaluations and, as such, the
methods of the economic evaluations are not critically
appraised; we simply report the results of the economic
evaluations that were conducted alongside included
interventions.
Evidence suggests that duration of intervention is a
predictor of effectiveness, for both the smoking cessa-
tion and weight loss studies; in the case of weight man-
agement, longer term weight loss may differ by setting.
Regression analysis showed that duration of intervention
accounted for some heterogeneity across the smoking
cessation studies. One longer term weight management
study compared interventions in a range of primary care
and commercial settings; all except the pharmacy and
GP groups resulted in significant weight loss at 1 year
compared with baseline. The data reported in the
studies identified for this review highlight the potential
importance of predictors of success.
In terms of the effects of the interventions on health
inequalities, some studies examined demographic and/
or socioeconomic factors at recruitment stage, as poten-
tial predictors of outcomes within group, and/or to
explain differences in retention. However, none of the
studies reported subgroup analysis of treatment effect by
SES. Three studies adopted a targeted approach to
addressing inequality, by recruiting participants from
deprived areas, and compared a pharmacy setting with
other settings. In two of these ‘targeted’ studies (one
smoking, one weight) the participants self-selected the
service; there were demographic and socioeconomic dif-
ferences between participants who self-selected treat-
ment by setting. The evidence shows that the
community pharmacy is an appropriate and feasible
setting to deliver a range of public health interventions,
and this setting has the potential to reach those most in
need.
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The original analysis plan included an examination of
any potential relationships between intervention effect-
iveness and behaviour change strategies and/or models
used, also whether any patterns existed between effective
interventions and implementation factors (eg, pharma-
cist training or resource intensity) or the organisation
and delivery of service (eg, stakeholder involvement).
Unfortunately, the lack of relevant data reported meant
that this analysis could not be undertaken. It is worth
noting that the majority of interventions were implemen-
ted within the political context of extending the public
health role of pharmacists.
These findings build on previous work; looking to the
future, there is a Cochrane review(46) in progress with a
broader remit than this review; it evaluates the effective-
ness of a wider variety of health promotion, or health
behaviour interventions, set in community pharmacy.
This work will further develop the evidence base; in par-
ticular, evidence regarding implementation, organisation
and delivery of other types of public health interventions
which may be transferable to alcohol reduction, smoking
cessation and weight management interventions.
Implications for policy and practice: The evidence shows a
range of types of smoking cessation interventions that
are feasible and effective within community pharmacies,
and supports the commissioning of smoking cessation
services in a community pharmacy setting. Smoking ces-
sation services, contracted as a core part of the national
contract, or part of a national ‘advanced’ service, may
well be a reasonable option. In addition, the evidence
shows that weight management services are no less
effective compared with those delivered in other
primary care settings. Therefore, given the potential
reach, effectiveness and associated costs of these inter-
ventions, commissioners may consider using community
pharmacies to help deliver some of their smoking cessa-
tion and weight management services.
Implications for future research: Further research is
required to assess the effectiveness of community
pharmacy-delivered alcohol reduction interventions, and
more research is needed on the cost-effectiveness of
community pharmacy-delivered alcohol, smoking and
weight management interventions compared with other
providers. It appears that the duration of intervention
impacts on effectiveness, and this is likely to impact on
cost-effectiveness. There is a lack of evidence regarding
the effect of community pharmacy-based interventions
for alcohol reduction, smoking cessation and weight loss
on health inequalities. Targeted intervention studies pro-
vided some evidence that adults accessing pharmacies
are a distinct group that may not access other primary
care or commercial organisations. This evidence is
derived from participants who self-selected the interven-
tion and setting. However, more research is required on
the reach of public health interventions delivered from
a community pharmacy setting. Future studies should be
sufficiently powered to detect small changes in behav-
ioural and health outcomes and measure the equity
effects of these small changes at a population level.
Future studies should assess and report sociodemo-
graphic and socioeconomic variables, behaviour change
strategies and models, implementation factors, the
organisation and delivery of interventions, and costs.
CONCLUSIONS
The evidence demonstrates that the community phar-
macy is an appropriate and feasible setting to deliver a
range of public health interventions. Community
pharmacy-delivered smoking cessation interventions are
effective and cost effective, particularly when compared
with usual care. Evidence from a heterogeneous group
of weight management interventions suggest that com-
munity pharmacy-delivered weight management inter-
ventions are as effective as similar interventions in other
primary care settings, at least in the short term, and
have similar provider costs. There is insufficient evi-
dence to assess the effectiveness of community
pharmacy-based interventions for alcohol reduction.
The impact of community pharmacy-delivered interven-
tions on inequalities in priority public health conditions
is unclear.
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